Phthalimide → HCID 69248953、化合物

HRID 1037550ノート

反応式

HRID 1037550 の反応式
[CH:1]1([C:4]2[C:12]([N:13]([CH2:18][CH2:19][CH2:20]O)[S:14]([CH3:17])(=[O:16])=[O:15])=[CH:11][C:10]3[C:6](=[C:7]([C:36]([NH:38][CH3:39])=[O:37])[N:8]([C:22]4[CH:27]=[CH:26][C:25]([NH:28][C:29]5[CH:34]=[CH:33][C:32]([F:35])=[CH:31][CH:30]=5)=[CH:24][CH:23]=4)[N:9]=3)[CH:5]=2)[CH2:3][CH2:2]1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.[C:59]1(=[O:69])[NH:63][C:62](=[O:64])[C:61]2=[CH:65][CH:66]=[CH:67][CH:68]=[C:60]12.N(C(OC(C)C)=O)=NC(OC(C)C)=O.CC(OC(/N=N/C(OC(C)C)=O)=O)C>C1COCC1>[CH:1]1([C:4]2[C:12]([N:13]([CH2:18][CH2:19][CH2:20][N:63]3[C:59](=[O:69])[C:60]4[C:61](=[CH:65][CH:66]=[CH:67][CH:68]=4)[C:62]3=[O:64])[S:14]([CH3:17])(=[O:16])=[O:15])=[CH:11][C:10]3[C:6](=[C:7]([C:36]([NH:38][CH3:39])=[O:37])[N:8]([C:22]4[CH:27]=[CH:26][C:25]([NH:28][C:29]5[CH:30]=[CH:31][C:32]([F:35])=[CH:33][CH:34]=5)=[CH:24][CH:23]=4)[N:9]=3)[CH:5]=2)[CH2:3][CH2:2]1

参加物

7

反応物 5

HCID 6809Phthalimide2 回HCID 11776Triphenylphosphine2 回HCID 75555Diisopropyl diazene-1,2-dicarboxylateHCID 5363146Diisopropyl azodicarboxylateHCID 675177915-Cyclopropyl-2-{4-[(4-fluorophenyl)amino]phenyl}-6-[(3-hydroxypropyl)(methylsulfonyl)amino]-N-methyl-2H-indazole-3-carboxamide

生成物 1

HCID 69248953HCID 69248953、化合物収率 326.4%

試薬・触媒・溶媒 1

HCID 8028Tetrahydrofuran溶媒

実験手順

To a solution of compound (ii) (5 mg, 0.009 mmol), triphenylphosphine (3.6 mg, 0.014 mmol) and phthalimide (2.0 mg, 0.014 mmol) in THF (0.5 mL) was added diisopropyl azodicarboxylate (2.7 μL, 0.014 mmol) at 0° C. After the mixture had been stirred at RT for 3.5 h, more triphenylphosphine (3.6 mg, 0.014 mmol), phthalimide (2.0 mg, 0.014 mmol) and DIAD (2.7 μL, 0.014 mmol) were added and stirring was continued at RT for a further 40 min. The solvent was removed in vacuo and the residue was purified by preparative LCMS (5-50-100% ACN in 0.1% aqueous formic acid) to afford 5-cyclopropyl-6-[3-(1,3-dioxoisoindolin-2-yl)propyl-methylsulfonyl-amino]-2-[4-(4-fluoroanilino)phenyl]-N-methyl-indazole-3-carboxamide (iii) as a white solid (20 mg, 81%).

後処理

  1. stirringstirring
  2. waitwas continued at RT for a further 40 min
  3. customThe solvent was removed in vacuo
  4. customthe residue was purified by preparative LCMS (5-50-100% ACN in 0.1% aqueous formic acid)

出典と根拠

ORDレコード
ord-8ca34f4bf575488a866f72b1f841972f
出典データセット
uspto-grants-2013_10
特許番号
US08546389B2

反応ノート

読み込み中…